



Technical Memorandum

To: Physicians, Clinical Staff and Clients

From: Wesley J. Kim, M.D. Ana Ortega-Lopez, M.D. Amy Powers, M.D.
DLS Medical Director Lab Director Lab Director

Date: October 7, 2025

Subject: Updates to PT/INR Result Reporting – Effective October 7, 2025

Effective October 7, 2025, Diagnostic Laboratory Services (DLS) will implement revisions to the reporting format for Prothrombin Time (PT) and International Normalized Ratio (INR) results. The purpose of these changes is to standardize reporting and improve the clarity of interpretive information provided to ordering clinicians.

Summary of Changes

- **Prothrombin Time (PT):**
 - No changes to result display or reference range.
- **International Normalized Ratio (INR):**
 - A reference range will now be included within the comment section of the report.
 - Only *critical values* will be flagged. The use of “L” (Low) and “H” (High) flags will be discontinued.

The following updated comments will appear in PT/INR reports:

Test Report Name	Reference range comment	
	Previous Comment	Updated Comment
PT/INR	Moderate-intensity Warfarin therapy 2.0-3.0	INR values should be used when evaluating patients on Vitamin K antagonist therapy. Reference and therapeutic ranges are below: Normal reference range for non-anticoagulated patients: 0.9-1.1
	High-intensity Warfarin therapy 2.5-3.5	Moderate-intensity Therapeutic range 2.0-3.0 High-intensity Therapeutic range 2.5-3.5

All providers are advised to review these changes carefully to ensure consistent interpretation and patient management.

If you have any questions, please call Client Services at 589-5101.